Cargando…
Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges
Diabetic retinopathy (more specifically diabetic macular edema, DME) is the most common cause of loss of vision in the working population in developed countries. Anti-vascular endothelial growth factor (anti-VEGF) agents considerably changed the treatment algorithms and improved prognosis of center-...
Autores principales: | Dervenis, Nikolaos, Mikropoulou, Athanasia Maria, Tranos, Paris, Dervenis, Panagiotis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487872/ https://www.ncbi.nlm.nih.gov/pubmed/28484955 http://dx.doi.org/10.1007/s12325-017-0548-1 |
Ejemplares similares
-
Dislocation of a previously successful XEN glaucoma implant into the anterior chamber: a case report
por: Dervenis, Nikolaos, et al.
Publicado: (2017) -
Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis, Nikolaos, et al.
Publicado: (2016) -
Intravitreal bevacizumab prior to vitrectomy for proliferative diabetic retinopathy: a systematic review
por: Dervenis, Panagiotis, et al.
Publicado: (2021) -
Update in treatment of uveitic macular edema
por: Koronis, Spyridon, et al.
Publicado: (2019) -
Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab
por: Yoshitake, Tatsuya, et al.
Publicado: (2019)